You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Article info

Article menu
Immunotherapy biomarkers
Original research
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Authors

  • Boris Duchemann Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, FranceFaculté de medecine, Université Paris-Saclay, Saint-Aubin, Île-de-France, France PubMed articlesGoogle scholar articles
  • Marie Naigeon Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, FranceFaculte de Pharmacie, Universite Paris-Saclay, Chatenay-Malabry, Île-de-France, France PubMed articlesGoogle scholar articles
  • Edouard Auclin Department of Oncology, Hôpital Européen Georges Pompidou Cancérologie, Paris, France PubMed articlesGoogle scholar articles
  • Roberto Ferrara Department of Medical Oncology, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy PubMed articlesGoogle scholar articles
  • Lydie Cassard Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Jean-Mehdi Jouniaux Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Lisa Boselli Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Jonathan Grivel Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Aude Desnoyer Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • François-Xavier Danlos LRTI, INSERM U1015, Gustave Roussy, Villejuif, FranceDépartement Innovations Thérapeutiques Essais Précoces, Institut Gustave-Roussy, Villejuif, France PubMed articlesGoogle scholar articles
  • Laura Mezquita Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Caroline Caramella Department of Radiology, Groupe hospitalier Paris Saint-Joseph, Paris, Île-de-France, France PubMed articlesGoogle scholar articles
  • Aurelien Marabelle LRTI, INSERM U1015, Gustave Roussy, Villejuif, Île-de-France, FranceDépartement Innovations Thérapeutiques Essais Précoces, Gustave Roussy, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Benjamin Besse Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, Île-de-France, FranceComité de pathologie thoracique, Gustave Roussy Institute, Villejuif, Île-de-France, France PubMed articlesGoogle scholar articles
  • Nathalie Chaput Laboratoire d’Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, Île-de-France, FranceFaculte de Pharmacie, Universite Paris-Saclay, Chatenay-Malabry, Île-de-France, France PubMed articlesGoogle scholar articles

Citation

Duchemann B, Naigeon M, Auclin E, et al
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
Journal for ImmunoTherapy of Cancer 2022;10:e004012. doi: 10.1136/jitc-2021-004012
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.